Flunivac’s approach

Our working hypothesis is that in order to develop a universal influenza vaccine that provides longer-lasting and broader protection against multiple strains of influenza virus both broad-reactive antibody (B-cell) and T-cell responses need to be induced.

FLUNIVAC therefore aims at developing a candidate influenza vaccine based on recombinant Modified Vaccinia virus Ankara viruses (rMVA) encoding both B-cell and T- cell response-inducing proteins, ready to commence Phase I clinical trials. We focus on influenza A virus since it is the most pathogenic variant to humans and causes all manifestations of human influenza: zoonotic, seasonal and pandemic.

 

Consortium

Rationale

Results

First periodic report